# MOTS-c: Evidence, Mechanism, Dosing & Legal Status

> A clinical monograph on MOTS-c — the 16-amino-acid mitochondrial-derived peptide marketed as an 'exercise mimetic' and metabolic regulator. Striking rodent data, no completed human efficacy trial, and an unsettled 2026 legal status.

*Published 2026-06-30 · Updated 2026-07-01 · By Elena Soto, PharmD*

The short answer
MOTS-c has genuinely striking *animal* data for metabolism, exercise capacity and healthspan, but **no completed human efficacy trial exists** — so its highest evidence grade is **C (preclinical only)**. The only solid human data are biomarker associations. It is not FDA-approved, sits in a 2026 regulatory gray zone, and is prohibited in sport at all times under WADA as an AMPK activator.[1](https://peptidevox.com/#r1)[8](https://peptidevox.com/#r8)

MOTS-c ("mitochondrial open reading frame of the 12S rRNA-c") is a 16-amino-acid mitochondrial-derived peptide marketed as an "exercise mimetic," insulin sensitizer and longevity candidate.[1](https://peptidevox.com/#r1) The rodent findings behind that hype are real and impressive; the human proof is not. This monograph separates the two.

*This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing guide. MOTS-c is not an FDA-approved drug; it is sold as a "research chemical not for human use" and is prohibited in sport. Dosing figures are reported strictly as seen in the published literature for completeness — not as recommendations. Consult a licensed clinician before any health decision.*

## What is MOTS-c and how does it work?

MOTS-c is a 16-amino-acid peptide translated from a small open reading frame embedded within the mitochondrial 12S rRNA gene — one of the founding members of the "mitochondrial-derived peptide" (MDP) family, alongside humanin and the SHLP series.[1](https://peptidevox.com/#r1) Because it is mitochondrially encoded, MOTS-c acts as a retrograde signal by which mitochondria communicate metabolic state to the nucleus.

The core mechanism — all of it preclinical — runs through the folate, AICAR and AMPK axis. MOTS-c inhibits the folate cycle at the 5-methyl-tetrahydrofolate step, which throttles de novo purine synthesis and causes accumulation of AICAR (5-aminoimidazole-4-carboxamide ribonucleotide), an established endogenous AMPK activator.[1](https://peptidevox.com/#r1) This lets MOTS-c engage AMP-activated protein kinase *without* first depleting cellular ATP — the property that makes it attractive as an exercise-mimetic signal active even under nutrient-replete conditions, and it also raises intracellular NAD⁺, potentially engaging SIRT1 upstream of AMPK.[1](https://peptidevox.com/#r1) Downstream, AMPK activation drives GLUT4 expression and glucose uptake in skeletal muscle and increases carnitine-shuttle activity and beta-oxidation, a profile of enhanced lipid utilization.[1](https://peptidevox.com/#r1) Under metabolic stress MOTS-c also translocates to the nucleus and modulates stress-adaptive transcription factors such as NRF2, positioning it as a mitohormetic stress regulator rather than a simple kinase switch.[3](https://peptidevox.com/#r3) A distinct immunometabolic mechanism has also been described, in which MOTS-c binds Raptor to inhibit mTORC1 and promote regulatory T-cell differentiation in a type-1-diabetes model.[3](https://peptidevox.com/#r3) Human pharmacokinetics are essentially absent: reviews explicitly flag that stability and oral bioavailability remain unresolved, and no validated half-life exists.[3](https://peptidevox.com/#r3)

## What is the evidence by indication?

Every efficacy indication below is supported by animal or in-vitro data only and graded C. The genuinely human data are limited to cross-sectional biomarker associations and the observation that exercise raises endogenous MOTS-c — neither of which demonstrates that *administering* the peptide benefits people.[3](https://peptidevox.com/#r3)

  MOTS-c evidence by indication

    IndicationBest evidenceGrade

    Insulin sensitivity / type 2 diabetesMouse glucose-tolerance & clamp studies; human serum is lower in poorly controlled T2DM (association only)C preclinical / B biomarker
    Obesity, visceral fat & hepatic steatosisMice: prevented diet-induced obesity without reduced food intake; analog trial registered, no published efficacyC (preclinical)
    Exercise capacity & age-related declineLate-life dosing roughly doubled treadmill capacity in old mice; exercise raises endogenous MOTS-c in humansC (preclinical)
    Longevity / healthspanExtended healthspan in mice; plasma MOTS-c declines with age; m.1382A>C longevity haplogroup associationC preclinical / D human assoc.
    Menopause-related metabolic & bone lossOvariectomized-mouse models: prevented weight gain, insulin resistance, bone lossC (preclinical)

The metabolic and exercise data are the most cited and the most extrapolated. In the foundational study, acute systemic MOTS-c reduced non-fasting glucose and improved glucose tolerance in mice, with a hyperinsulinemic-euglycemic clamp localizing the effect to skeletal-muscle glucose clearance; injections in 12-month-old mice reversed age-dependent muscle insulin resistance.[1](https://peptidevox.com/#r1) In the most striking dataset, intermittent MOTS-c given late in life (at 23.5 months) roughly doubled treadmill running capacity in old mice, who outran untreated middle-aged controls, and improved healthspan.[2](https://peptidevox.com/#r2)[14](https://peptidevox.com/#r14) In humans, exercise itself induces about a 12-fold rise in skeletal-muscle MOTS-c and a 1.6-fold rise in circulation — establishing it as an exercise-responsive peptide, not proving that injecting it improves performance.[2](https://peptidevox.com/#r2)

The human record is otherwise observational. Cross-sectional cohorts show serum MOTS-c is lower in poorly controlled type 2 diabetes and in obese children, and plasma MOTS-c declines progressively with age.[3](https://peptidevox.com/#r3) A 12-week structured exercise program in breast-cancer survivors was studied for its effect on circulating MOTS-c — a biomarker-response study, not a test of MOTS-c as a drug.[6](https://peptidevox.com/#r6)[7](https://peptidevox.com/#r7) The first controlled efficacy trial, a Phase 2a RCT of subcutaneous MOTS-c in prediabetes and obesity with the Matsuda insulin-sensitivity index at 12 weeks as a co-primary endpoint, is registered as [NCT07505745](https://clinicaltrials.gov/study/NCT07505745) and began recruiting in February 2026, with no results at the time of writing.[5](https://peptidevox.com/#r5)

Proven vs hyped
The mechanism is well-characterized and the rodent metabolic and exercise data are genuinely striking — but every efficacy claim is grade C. The most defensible human takeaway is almost the inverse of the marketing: MOTS-c is a *marker and mediator* of the benefits of actual exercise. The durable way to raise it today is to train and eat well, not to inject an unregulated peptide.[2](https://peptidevox.com/#r2)

## What doses appear in the literature?

Reported strictly as information, not a protocol — no dose has been validated for human efficacy or safety. Rodent studies used intraperitoneal injection in intermittent regimens (for example, three times per week in the longevity work), but standardized milligram-per-kilogram figures are not reproduced in the review literature.[2](https://peptidevox.com/#r2) The Phase 2a human trial administers a fixed once-daily subcutaneous dose for 12 weeks, followed through Week 16 for safety, though the exact milligram amount is not disclosed in the public registry.[5](https://peptidevox.com/#r5) Anecdotal online "research" use describes subcutaneous self-administration commonly cited around 5 to 10 milligrams per week from lyophilized powder reconstituted with bacteriostatic water — figures that are unverified, have no clinical basis, and originate from products labeled not for human use.[8](https://peptidevox.com/#r8) No pharmacopeial product or validated reconstitution standard exists because MOTS-c is unapproved.[8](https://peptidevox.com/#r8)

## How safe is MOTS-c?

Controlled human safety data do not exist; USADA notes that no completed clinical trials exist, so safe conditions of use are unknown.[8](https://peptidevox.com/#r8) The first systematic safety capture — treatment-emergent adverse events plus anti-drug-antibody immunogenicity — is an endpoint of the ongoing Phase 2a trial.[5](https://peptidevox.com/#r5) Among online users (uncontrolled, confounded by product quality), reported effects include elevated heart rate or palpitations, injection-site irritation, insomnia and fever.[8](https://peptidevox.com/#r8) The dominant regulator-flagged hazard is contamination, not an intrinsic toxicity: the FDA's 2023 Category-2 placement cited immunogenicity risk for some routes, peptide-related impurities, and inadequate API characterization.[10](https://peptidevox.com/#r10) Mechanistically, additive hypoglycemia is conceivable if combined with insulin or insulin secretagogues, and folate-cycle and nucleotide-pathway interference warrants caution in any rapidly dividing-tissue context, though no carcinogenicity signal has been reported.[3](https://peptidevox.com/#r3) Pregnancy and lactation, active malignancy and renal impairment are sensible exclusions — the Phase 2a trial excludes established diabetes, recent cardiovascular events, eGFR below 60, active malignancy and pregnancy.[5](https://peptidevox.com/#r5)

## What is the FDA and WADA status in 2026?

MOTS-c is not an FDA-approved drug for any indication and has no NDA or BLA; it is sold "for research use only, not for human use."[8](https://peptidevox.com/#r8) The regulatory timeline is precise: in 2023 the FDA placed MOTS-c among roughly 17–19 peptides in 503A Category 2, citing immunogenicity, impurity and characterization concerns.[10](https://peptidevox.com/#r10)[12](https://peptidevox.com/#r12) A guidance effective January 7, 2025 ended the Category 1/2/3 system for newly nominated substances while leaving former Category 2/3 substances prohibited pending action.[13](https://peptidevox.com/#r13) On April 15, 2026, HHS and FDA announced removal of 12 peptides including MOTS-c from Category 2 — attributed to withdrawal of nominations — effective around April 23, 2026.[11](https://peptidevox.com/#r11)[10](https://peptidevox.com/#r10) The critical caveat: removal from Category 2 does not authorize compounding; it removes the explicit prohibition designation but does not add MOTS-c to the 503A authorized bulks list, which requires a separate Pharmacy Compounding Advisory Committee review scheduled for July 23, 2026.[10](https://peptidevox.com/#r10) As of mid-2026, pharmacies cannot lawfully compound MOTS-c.

For athletes the picture is unambiguous. MOTS-c has been on the WADA Prohibited List since January 1, 2024, listed by full name under category S4.4.1 (Activators of AMP-activated protein kinase) — prohibited at all times, in and out of competition, with no Therapeutic Use Exemption.[8](https://peptidevox.com/#r8)[9](https://peptidevox.com/#r9) The status is unchanged for 2026, and it is not a DEA-controlled substance — it is regulated as an unapproved drug, not a scheduled one.[8](https://peptidevox.com/#r8)

**Bottom line.** MOTS-c pairs a biologically compelling mechanism and genuinely striking rodent data with a near-total absence of human proof. The gap between promise and proof is the headline — graded C, legally unsettled, and banned in sport. Regulatory facts here are current as of June 2026; the July 23, 2026 PCAC outcome and the Phase 2a trial results were pending at the time of writing and should be re-verified after those dates.

---
Source: https://peptidevox.com/peptide-encyclopedia/mots-c
Index: https://peptidevox.com/llms.txt · Full text: https://peptidevox.com/llms-full.txt